Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 04/01 05:10:00 am
405.925 DKK   -0.79%
03/30NOVO NORDISK A/S : - Share repurchase programme
AQ
03/27NOVO NORDISK AS : Ex-dividend day for final dividend
FA
03/26NOVO NORDISK A/S : - Articles of Association
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Notice for the Annual General Meeting of Novo Nordisk A/S

share with twitter share with LinkedIn share with facebook
share via e-mail
02/21/2020 | 02:02am EDT

Bagsværd, Denmark, 21 February 2020 – The Annual General Meeting of Novo Nordisk A/S will be held on:


Thursday 26 March 2020 at 2.00 pm (CET) 
at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark.


The notice for the Annual General Meeting, including Appendix 1: Proposed Remuneration Policy and Appendix 2: Candidates for the Board of Directors is enclosed.

BOARD OF DIRECTORS

All board members elected by the Annual General Meeting are up for election.

The Board of Directors proposes re-election of all board members elected by the Annual General Meeting: Helge Lund (chairman) Jeppe Christiansen (vice chairman), Brian Daniels, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Liz Hewitt, Kasim Kutay and Martin Mackay.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:  
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com
   
Investors:  
Daniel Bohsen+45 3075 2175dabo@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com

Company announcement No 12 /2020

Attachment

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
03/30NOVO NORDISK A/S : - Share repurchase programme
AQ
03/27NOVO NORDISK AS : Ex-dividend day for final dividend
FA
03/26NOVO NORDISK A/S : - Articles of Association
AQ
03/26Resolutions from the Annual General Meeting of Novo Nordisk A/S
GL
03/26NOVO NORDISK A/S : Proxy Statments
CO
03/23NOVO NORDISK A/S : Disclosure of transaction data
PU
03/23NOVO NORDISK A/S : Share repurchase programme
PU
03/18NOVO NORDISK A/S : e-therapeutics plc - Results for the year ended 31 January 20..
AQ
03/17NOVO NORDISK A/S : pauses the clinical trials investigating concizumab in haemop..
AQ
03/16Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI m..
GL
More news
Financials (DKK)
Sales 2020 130 B
EBIT 2020 55 035 M
Net income 2020 42 324 M
Finance 2020 13 192 M
Yield 2020 2,22%
P/E ratio 2020 22,6x
P/E ratio 2021 20,0x
EV / Sales2020 7,30x
EV / Sales2021 6,83x
Capitalization 960 B
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 416,13  DKK
Last Close Price 409,15  DKK
Spread / Highest target 22,2%
Spread / Average Target 1,71%
Spread / Lowest Target -29,1%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S5.82%141 503
JOHNSON & JOHNSON-8.82%345 705
ROCHE HOLDING AG0.02%277 060
MERCK & CO., INC-15.40%195 141
NOVARTIS-13.11%187 703
PFIZER, INC.-16.69%181 075